跳至主要内容
临床试验/NCT06122753
NCT06122753尚未招募不适用

Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT): A Multicenter Randomized Trial

West China Hospital1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2024年1月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
120
试验地点
1
主要终点
6-week mortality

研究概览

简要总结

Portal vein thrombosis (PVT) can lead to a further increase in portal venous pressure and increase the risk of rebleeding. Whether patients with acute esophagogastric variceal bleeding with occlusive PVT benefit from preemptive TIPS is still controversial. The present study is directed at comparing the outcome of patients with acute variceal bleeding with occlusive PVT treated by standard therapy (vasoactive drugs + endoscopic variceal ligation) with or without preemptive TIPS (performed during the first 1-3 days after endoscopic procedure). The primary outcome is survival free of variceal rebleeding at 6 weeks from inclusion.

详细描述

Portal vein thrombosis (PVT) is a common complication in patients with cirrhosis, and the cumulative incidence of PVT is 4.6%, 8.2%, and 10.7% at 1 year, 3 years, and 5 years, respectively. PVT can lead to a further increase in portal venous pressure and increase the risk of rebleeding. According to Baveno VII, PVT can be classified according to the degree of occlusion of the portal trunk as complete occlusion (no continuous luminal structure), partial occlusion (≥50% thrombus obstruction of the lumen), mild occlusion (<50% thrombus obstruction of the lumen), or spongiotic degeneration (a large number of collateral vessels of the portal vein, with no visualization of the main portal vein). The results of a recent observational study suggested that patients with severe PVT with ≥50% thrombotic luminal obstruction had higher 6-week rebleeding rates (8.8% vs. 3.8%) and 1-year rebleeding rates (29.4% vs. 21.4%) after acute variceal bleeding. Our previous clinical study showed that patients with cirrhotic PVT treated with TIPS had lower rebleeding rates and significantly higher rates of portal vein recanalization, and it was inferred that patients with acute esophagogastric variceal bleeding with severe PVT might benefit from preemptive TIPS. Therefore, we propose to conduct a multicentre randomized controlled trial to enroll patients with acute esophagogastric variceal bleeding with occlusive PVT to compare the preemptive TIPS with the standardized therapy. The outcomes are rates of mortality, rebleeding, and complications.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cirrhosis (diagnosed by imaging, laboratory tests, clinical symptoms, or liver biopsy);
  • Admission due to acute bleeding from esophagogastric varices;
  • Thrombus in the main trunk of the portal vein occupying ≥50% of the lumen.

排除标准

  • Prior treatment with TIPS or surgical shunt;
  • Presence of contraindications to endoscopic treatment, carvedilol, or TIPS;
  • Presence of hepatocellular carcinoma exceeding Milan criteria;
  • Presence of other systemic malignant tumors with expected survival time not exceeding 6 months;
  • Presence of uncontrollable infection or sepsis;
  • Presence of cardiac, pulmonary, or renal failure;
  • Pregnant or lactating women;
  • Refusal to sign the informed consent form.

结局指标

主要结局

6-week mortality

时间窗: 6 weeks

The rate of mortality during the first 6 weeks after inclusion in the study.

次要结局

  • 5-day treatment failure(5 days)
  • decompensation events(1 year)
  • adverse events(1 year)
  • 1-year mortality(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

luo xuefeng

Professor

West China Hospital

研究点 (1)

Loading locations...

相似试验